For a patient with a diffuse leptomeningeal glioneuronal tumor, is combined dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) appropriate, and what monitoring is required?

Dabrafenib and Trametinib for Diffuse Leptomeningeal Glioneuronal Tumor

For patients with diffuse leptomeningeal glioneuronal tumor (DLGNT) harboring a BRAF V600E mutation, combined dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) is an appropriate and potentially highly effective treatment option, particularly given the near-universal presence of KIAA1549::BRAF fusions in this disease.

Evidence Supporting Use in DLGNT

The rationale for this recommendation stems from multiple lines of evidence:

Molecular Profile Alignment

DLGNT demonstrates KIAA1549::BRAF fusion in 96.4% of cases 1, making it a BRAF-driven tumor. While this differs from the V600E point mutation, the downstream MAPK pathway activation is similar, and pediatric CNS guidelines explicitly support BRAF/MEK inhibition for BRAF-altered tumors 2.

Direct Evidence in Similar Entities

Two pediatric case reports demonstrate dramatic responses in high-grade gliomas with leptomeningeal metastases treated with dabrafenib/trametinib, showing rapid symptom improvement within days and radiographic remission of both brain and spinal lesions within one month 3. A larger study of 30 patients with BRAF V600E-mutated CNS tumors showed a 76% clinical benefit rate and median progression-free survival of 18.1 months 4.

Broader CNS Tumor Experience

The ROAR basket trial demonstrated objective response rates of 33% in high-grade gliomas and 69% in low-grade gliomas with BRAF V600E mutations 5. Pediatric-specific dosing has been established, with response rates of 15-25% in BRAF V600-mutant gliomas 6.

Treatment Protocol

Dosing

• Adults and children ≥6 years: Dabrafenib 150 mg PO twice daily + Trametinib 2 mg PO once daily 2, 5
• Children <6 years: Weight-based dosing at 0.032 mg/kg once daily for trametinib 6
• Continue until disease progression or unacceptable toxicity

Critical Monitoring Requirements

Baseline assessments:

• Complete MRI brain and total spine with contrast (use 3 Tesla scanner with 3D T1 post-contrast sequences, 1mm isotropic voxels) 7
• CSF cytology and molecular analysis if feasible
• Cardiac evaluation including echocardiogram or MUGA scan (baseline ejection fraction)
• Ophthalmologic examination
• Complete blood count, comprehensive metabolic panel
• Dermatologic examination

Ongoing surveillance:

• Weekly for first month: Monitor for pyrexia (occurs in 25-77% of patients) 8
• Every 2-4 weeks initially, then monthly: CBC, CMP, liver function tests
• Every 2-3 months: Cardiac function assessment (echocardiogram/MUGA)
• Every 2-3 months: MRI brain and spine using same scanner/protocol 7
• Every 3 months: Ophthalmologic examination for retinal vein occlusion
• Ongoing: Dermatologic surveillance for cutaneous squamous cell carcinoma/keratoacanthoma (6% incidence with dabrafenib) 9

Toxicity Management

Common Adverse Events

The combination demonstrates manageable toxicity in pediatric and adult CNS tumors:

• Pyrexia (25-77%): Most common dose-limiting toxicity. Manage with acetaminophen/NSAIDs and temporary drug interruption 9, 8
• Fatigue, headache, chills: Grade 1-2 in majority 8
• Gastrointestinal: Diarrhea, nausea (22-29%) 10
• Hematologic: Neutropenia (9% grade 3-4) 11

Dose Modifications

Expect dose reductions in 81.5% of patients 10. For grade 3 toxicity, hold both drugs until recovery to grade ≤1, then resume at reduced dose. For recurrent grade 3 or any grade 4 toxicity, consider permanent discontinuation.

Serious Adverse Events

• Cardiac: Decreased ejection fraction (8%) requires dose interruption 11
• Hemorrhagic events: Rare but reported (intracranial, GI) 11
• Secondary malignancies: Cutaneous SCC/keratoacanthoma (6%) - requires dermatologic excision but not drug discontinuation 9

Clinical Context and Caveats

DLGNT-specific considerations:

• Patients >9 years at diagnosis have worse outcomes (5-year OS 83.3% overall) 1
• Disease is often disseminated at presentation (46.7% in one series) 1
• Chemotherapy remains first-line in many centers, with median PFS of 44 months 1
• Targeted therapy showed median PFS of only 18 months in the DLGNT cohort, though numbers were small 1

The decision to use dabrafenib/trametinib should prioritize:

1. Confirmation of BRAF alteration (V600E mutation or KIAA1549::BRAF fusion)
2. Progressive or symptomatic disease despite conventional therapy
3. Patient age and ability to comply with intensive monitoring
4. Absence of contraindications (severe cardiac dysfunction, uncontrolled bleeding risk)

Alternative approaches include chemotherapy (vincristine/carboplatin/temozolomide showing 44-month median PFS) 1 or radiation therapy, though the latter carries significant neurotoxicity risk in young patients 2.

The combination represents a rational, biologically-targeted approach for this rare, challenging disease, with the caveat that DLGNT-specific outcome data remain limited and multi-omic analysis suggests multiple activated pathways may require combination strategies beyond BRAF/MEK inhibition alone 1.